Comparing trials like Sequoia (zanubrutinib) and Amplify (acalabrutinib-venetoclax) is invalid without adjusting for baseline population differences. Amplify's inclusion of an FCR chemo-arm meant its patients were inherently more fit, necessitating statistical matching for a fair comparison.

The next wave of CLL research is moving beyond a standard one-year fixed duration. Ongoing studies now use Minimal Residual Disease (MRD) results to tailor treatment length, personalizing care by potentially shortening, extending, or adding therapies based on a patient's individual depth of response.

The SEQUOIA study showed that for high-risk CLL patients (e.g., p53 mutated), extending treatment with zanubrutinib and venetoclax beyond the planned duration significantly increases rates of undetectable MRD. This suggests a personalized, response-adapted approach, challenging the rigid concept of "fixed-duration" for all.

The CLL17 study revealed a significant difference in undetectable Minimal Residual Disease (UMRD) rates between treatment arms, yet Progression-Free Survival (PFS) curves were not statistically different. This challenges the assumption that UMRD can consistently serve as a direct proxy for long-term survival outcomes in all contexts.

The UK FLAIR trial demonstrated for the first time that a time-limited regimen (ibrutinib-venetoclax), guided by MRD to a median duration of 27 months, achieved superior progression-free and overall survival compared to continuous ibrutinib therapy in frontline CLL.

A negative Minimal Residual Disease (MRD) result is not a universal surrogate for Progression-Free Survival (PFS). Its predictive power is context-dependent; it's meaningful when comparing similar treatments (e.g., BTKi + BCL2i vs. another BTKi + BCL2i), but less so when comparing entirely different drug classes.

The zanubrutinib-venetoclax arm of the SEQUOIA trial, while technically 'MRD-guided', had such strict criteria for stopping treatment (e.g., two bone marrow biopsies) that very few patients qualified. This design flaw meant most patients effectively received continuous zanubrutinib after the initial combination phase.

The FLAIR trial's MRD-guided protocol, while effective, created a paradox. Lower-risk, IGHV-mutated patients, who typically do well on shorter treatments, took longer to achieve undetectable MRD. This resulted in them receiving a longer duration of therapy than their higher-risk counterparts, representing likely overtreatment.

The CLL17 study reveals that continuous ibrutinib, fixed-duration venetoclax/obinutuzumab, and fixed-duration venetoclax/ibrutinib all yield identical progression-free survival rates at three years. This finding empowers clinicians to choose a strategy based on patient preference (continuous vs. fixed-duration) without compromising near-term efficacy.